Search

Displaying results 4861 - 4870 of 5895 in total
  1. Drug

    Difloxacin

    go.drugbank.com/drugs/DB11511
    ExperimentalVet approved

    However, it presents a reduced efficacy when compared to other fluoroquinolone antibacterials.

  2. Drug

    Ketazocine

    go.drugbank.com/drugs/DB20132
    Experimental

    The usage of the INN stem '-azocine' in the name indicates that Ketazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Ketazocine has a monoisotopic molecular weight of 285.17 Da.

  3. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    Barbexaclone exists in 25mg and 100mg tablets. 100mg of barbexaclone is equivalent to 60mg of phenobarbital. … While barbexaclone has sedative properties, propylhexedrine has psychostimulant properties intended to offset these sedative effects.

  4. Drug

    Oportuzumab monatox

    go.drugbank.com/drugs/DB05319
    Investigational

    VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells.

  5. Drug

    Onapristone

    go.drugbank.com/drugs/DB12637
    Investigational

    treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no

  6. Drug

    Puromycin

    go.drugbank.com/drugs/DB08437
    Experimental

    Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.

  7. Drug

    Glycochenodeoxycholic Acid

    go.drugbank.com/drugs/DB02123
    Experimental

    It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is a cholagogue and choleretic. [PubChem]

  8. Drug

    Eptazocine

    go.drugbank.com/drugs/DB19670
    Experimental

    The usage of the INN stem '-azocine' in the name indicates that Eptazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Eptazocine has a monoisotopic molecular weight of 231.16 Da.

  9. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.

  10. Drug

    Deferitazole

    go.drugbank.com/drugs/DB13120
    Investigational

    It has been used in trials studying the treatment and basic science of Beta-thalassemia, Hepatic Impairment, Impaired Renal Function, Transfusional Iron Overload, and Iron Overload Due to Repeated Red